NCT02286089View on ClinicalTrials.gov

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

January 31, 2031

Conditions
Age-Related Macular Degeneration
Interventions
BIOLOGICAL

OpRegen

Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.

Trial Locations (7)

19107

Mid Atlantic Retina, Philadelphia

45242

Cincinnati Eye Institute, Cincinnati

76100

Kaplan Medical Center, Rehovot

94109

West Coast Retina Medical Group, San Francisco

4941492

Rabin Medical Center, Petah Tikva

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

9112001

Hadassah Medical Center, Jerusalem

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02286089 - Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter